148 related articles for article (PubMed ID: 37250283)
1. Locoregional Control Benefit of a Tumor Bed Boost for Ductal Carcinoma In Situ.
Dreyfuss AD; Max D; Flynn J; Zhang Z; Gillespie EF; Xu A; Cuaron J; Mueller B; Khan AJ; Cahlon O; Powell SN; McCormick B; Braunstein LZ
Adv Radiat Oncol; 2023; 8(5):101254. PubMed ID: 37250283
[TBL] [Abstract][Full Text] [Related]
2. Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
Rakovitch E; Sutradhar R; Lalani N; Nofech-Mozes S; Gu S; Goldberg M; Hanna W; Fong C; Paszat L
Breast Cancer Res Treat; 2019 Nov; 178(1):169-176. PubMed ID: 31325071
[TBL] [Abstract][Full Text] [Related]
3. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
[TBL] [Abstract][Full Text] [Related]
4. Minimally invasive tumor bed implant (MITBI) and peri-operative high-dose-rate brachytherapy (PHDRBT) for accelerated minimal breast irradiation (AMBI) or anticipated boost (A-PHDRBT-boost) in breast-conserving surgery for ductal carcinoma in situ.
Morales MG; Martinez-Regueira F; Rodriguez-Spiteri N; Olartecoechea B; Rubio I; Esgueva A; Pina L; Elizalde A; Sampedro CS; Idoate MA; Abengozar M; Ramos L; Manuel FC; MartÃnez-Monge R; Cambeiro M
J Contemp Brachytherapy; 2020 Dec; 12(6):521-532. PubMed ID: 33437299
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
6. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy.
Rodin D; Sutradhar R; Nofech-Mozes S; Gu S; Faught N; Hahn E; Fong C; Trebinjac S; Paszat L; Rakovitch E
Breast Cancer Res Treat; 2022 Feb; 192(1):223-233. PubMed ID: 35083587
[TBL] [Abstract][Full Text] [Related]
8. A low risk of recurrence after breast-conserving surgery for DCIS: A single-institution experience.
van Bekkum S; Drukker C; van Rosmalen J; Menke-Pluijmers MBE; Westenend PJ
Cancer Treat Res Commun; 2023; 35():100706. PubMed ID: 37058969
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery plus radiotherapy: a preliminary report.
Jang JY; Ryu MR; Kim SW; Kay CS; Kim YS; Oh YK; Kwon HC; Yoon SC; Park WC; Song BJ; Oh SJ; Jung SS; Won JM; Kim SN; Chung SM
Cancer Res Treat; 2005 Dec; 37(6):344-8. PubMed ID: 19956370
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated radiation therapy for breast ductal carcinoma in situ.
Hathout L; Hijal T; Théberge V; Fortin B; Vulpe H; Hogue JC; Lambert C; Bahig H; Provencher L; Vavassis P; Yassa M
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1058-63. PubMed ID: 24113057
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
12. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
Pawloski KR; Tadros AB; Sevilimedu V; Newman A; Gentile L; Zabor EC; Morrow M; Van Zee KJ; Kirstein LJ
Breast Cancer Res Treat; 2021 Apr; 186(3):617-624. PubMed ID: 33675490
[TBL] [Abstract][Full Text] [Related]
13. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
Thompson AM; Clements K; Cheung S; Pinder SE; Lawrence G; Sawyer E; Kearins O; Ball GR; Tomlinson I; Hanby A; Thomas JSJ; Maxwell AJ; Wallis MG; Dodwell DJ;
Eur J Cancer; 2018 Sep; 101():210-219. PubMed ID: 30092498
[TBL] [Abstract][Full Text] [Related]
14. Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed.
Wazer DE; Schmidt-Ullrich RK; Ruthazer R; Schmid CH; Graham R; Safaii H; Rothschild J; McGrath J; Erban JK
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):851-8. PubMed ID: 9531370
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins.
Suzuki R; Yoshida M; Oguchi M; Yoshioka Y; Tokumasu K; Osako T; Ono S; Ueno T; Miyagi Y
J Radiat Res; 2020 May; 61(3):440-446. PubMed ID: 32163143
[TBL] [Abstract][Full Text] [Related]
16. Significance of boost radiotherapy in early invasive ductal breast cancer with ductal carcinoma in situ component under negative surgical margins.
Shimizu N; Myojin M; Tamura M; Nishiyama N; Yamashiro K; Yuyama Y; Okazaki Y; Suzuki Y; Takahashi M
J Radiat Res; 2022 Jan; 63(1):80-87. PubMed ID: 34718690
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy.
Kestin LL; Goldstein NS; Lacerna MD; Balasubramaniam M; Martinez AA; Rebner M; Pettinga J; Frazier RC; Vicini FA
Cancer; 2000 Feb; 88(3):596-607. PubMed ID: 10649253
[TBL] [Abstract][Full Text] [Related]
19. Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?
Yerushalmi R; Sulkes A; Mishaeli M; Neumann A; Dinerman M; Sulkes J; Rizel S; Yarom N; Gutman H; Fenig E
Neoplasma; 2006; 53(6):507-10. PubMed ID: 17167720
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
